ClinicalTrials.gg
CompletedNCT05665283Updated Feb 20, 2024

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

A Phase 1 interventional study of Ensartinib Hydrochloride in Bioequivalency, sponsored by Xcovery Holdings, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Xcovery Holdings, Inc. (part of Betta Pharmaceuticals Co., Ltd.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, Phase I single dose 2-part, crossover bioequivalence study under fasted conditions. The trial is designed to evaluate the pharmacokinetic parameters between single doses of 100mg ensartinib capsules manufactured by two different processes.

Read the detailed description

A Phase I, randomized, open-label single dose, 2-part, crossover bioequivalence study under fasted conditions to compare 100 mg capsules manufactured using the proposed commercial manufacturing process to the corresponding capsules which were utilized in the Phase III clinical study manufactured by a different process. A total of 32 healthy subjects were divided evenly and were randomized into 1 of the 2 treatment sequences (T-R or R-T) prior to Period 1 dosing. Subjects received the test product (100 mg ensartinib hydrochloride capsules manufactured with the registration stability process) or the reference product (100 mg ensartinib hydrochloride capsules utilized in the Phase 3 trial) according to their assigned treatment sequence.

The single dose crossover study will have a minimum washout period of 14 days.

02

Conditions studied

  • Bioequivalency

Keywords

  • Bioequivalency
  • Phase I
03

In context

Lead sponsor

Xcovery Holdings, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females of non- and males age 18\~55 years. Female subjects must be of non-childbearing potential (according to Appendix A), and have a negative serum pregnancy test at screening and a negative urine pregnancy test at (each) admission to the clinical research center.
  2. Male subjects with female partners of child-bearing potential must use two forms of acceptable (according to Appendix A).
  3. Male body weight ≥ 50.0 kg or female body weight ≥ 45.0 kg; between 18.0-32.0 kg/m2.
  4. Generally in good health, with no history of any (in the opinion of the Investigator) , chronic or serious cardiovascular, hepatic, renal, respiratory, blood and lymphatic system, endocrine, immune, mental, neurological, gastrointestinal diseases. Additionally, no abnormalities of clinical significance in vital sign examination, physical examination, clinical laboratory tests (blood routine, urinalysis, blood biochemistry, drug test, nicotine test, etc.), and 12-lead .
  5. No plan for sperm or egg donation during screening and for the next 6 months.
  6. Able to provide written, before initiation of any study related procedures, and is able, in the opinion of the Investigator, to comply with all the requirements of the study.
  7. Able to swallow oral medication.
  8. Able to communicate well with the investigator and understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. History of allergies or to any (microcrystalline cellulose, stearic acid, hydroxypropyl methylcellulose, or tartrazine, (a dye used in the ensartinib 100 mg capsules) or aspirin, or history of allergies to two or more kinds of drugs or foods.
  2. History of , in the opinion of the investigator, dysphagia or history of any gastrointestinal diseases that may affect drug absorption.
  3. Received surgery within 3 months of the first dose, a history or have plans for a surgery during the study, that might affect absorption, distribution, metabolism, and excretion of drugs (e.g., gastrectomy, cholecystectomy, or other gastrointestinal tract surgery, except appendectomy).
  4. The presence of diseases with abnormal clinical manifestations that need to be excluded, in the opinion of the investigator, including but not limited to nervous, cardiovascular, blood and lymphatic system, immune, renal, hepatic, gastrointestinal, respiratory, metabolic and skeletal diseases.
  5. Venipuncture intolerance or history of blood phobia and needle sickness.
  6. Drug abuse within 3 months of the first dose.
  7. Donated ≥200 mL of blood (blood components) or had massive blood loss, received blood transfusion or blood products within 3 months of the first dose.
  8. Males who are planning a pregnancy with a partner or sperm donation in upcoming 6 months.
  9. The use of potent inhibitors or inducers (see Appendix C in the trial protocol for details) and potent P-gp inhibitors (verapamil, cyclosporine A, dexverapamil) within 2 weeks before first dose.
  10. Received any prescription drug, over-the-counter drug, herbal drug or vitamins within 2 weeks of the first dose. An exception is made for incidental use of acetaminophen or an NSAID, which is allowed up to admission to the clinical research center.
  11. Received any vaccine within 4 weeks of the first dose.
  12. Excessive smoking (more than 5 cigarettes/day) within 3 months of the first dose, or disagreed on avoiding use of any tobacco products during the trial.
  13. Excessive alcohol use (more than 14 units of alcohol per week) (1 unit of alcohol ≈ 360 mL of beer, 45 mL of liquor at 40% ABV, or 150 mL of wine) within 3 months of the first dose, or unwilling to quit alcohol during the trial.
  14. Excessive tea, coffee and/or caffeinated beverages (more than 8 cups, 250 ml for each cup) every day within 3 months of the first dose (amount based on investigator opinion)
  15. Consumption of excessive dragon fruit, mango, pomelo, lime, carambola, or food or beverage products prepared within 7 days of the first dose (amount based on investigator opinion).
  16. Have a special diet requirement and cannot accept an uniform diet.
  17. The presence of abnormal vital sign findings of clinical significance. Normal ranges for reference (including cutoffs): systolic blood pressure 90\~139 mmHg, diastolic blood pressure 50-89 mmHg, pulse 40-100 beats/min, temperature (oral) 35.4-37.7 °C, and breathing 10-20 breaths/min at a sitting position. The specific results are comprehensively judged by the investigator.
  18. Abnormal findings in any item of laboratory tests and auxiliary tests, which are of clinical significance at the investigator's discretion.
  19. Subject has any history of (HIV) or immunodeficiency or known diagnosis of or C.
  20. Subject has history or diagnosis of cancer with the exception of basal cell carcinoma treated more than 3 years prior to first dose and without a recurrence.
  21. An alcohol level greater than 0.0 mg/100mL as indicated by an alcohol breath test (ABT) or drug abuse screening test (morphine, methamphetamine, ketamine, ecstasy, and cannabis) positive.
  22. Between screening and (first) admission on day -1: Those who had diseases or took drugs ineligible for enrollment in the opinion of the investigator in this period; Those who ate methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks) or grapefruit (juice) from 48 hours (2 days) prior to (first) admission.
  23. Previous participation in this study or subjects that are deemed by the investigator as not appropriate for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Reference Standard Group

    In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product. In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes.

    Drug: Ensartinib Hydrochloride

  • Active comparator
    Test Standard Group

    In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product. In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes.

    Drug: Ensartinib Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed concentration

    Time frame: 14 Days

  2. AUC(0-t)

    Area under the concentration time curve from time 0 to time of the last quantifiable

    Time frame: 14 Days

  3. AUC(0-∞)

    Area under the concentration time curve from time 0 to infinity

    Time frame: 14 Days

Secondary outcomes

  1. tmax

    Time to reach maximum observed plasma concentration

    Time frame: 14 Days

  2. t1/2

    Apparent terminal elimination half life

    Time frame: 14 Days

  3. lz

    Terminal Phase elimination rate constant

    Time frame: 14 Days

07

Study locations

1 site
  • ICON - Early Development Services
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jan 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2022
First posted
Dec 27, 2022
StartActual
Nov 29, 2022
Primary completionActual
Jan 18, 2023
CompletionActual
Aug 8, 2023
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05665283
Responsible party
Sponsor
First posted
Dec 27, 2022
Start date
Nov 29, 2022
Primary completion
Jan 18, 2023
Completion
Aug 8, 2023
Last update
Feb 20, 2024

Study contacts

Giovanni Selvaggi, MD
principal investigator · Xcovery Holdings, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion